Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02442258 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and Impaired Renal Function
A Phase 1 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT02442258 is a Phase 1 study that has completed, run by AbbVie. The registered enrollment target is 46 participants.
The verdict
NCT02442258, a Phase 1 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
This is an open-label, single dose study designed to assess the pharmacokinetics and safety of ABT-493 and ABT-530 in subjects with either normal renal function or impaired renal function.
Interventions
- DRUG ABT-493
- DRUG ABT-530
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2015-03 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02442258
The ClinicalTrials.gov registry entry for NCT02442258 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ABT-493 is the first listed.
NCT02442258 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02442258 about?
NCT02442258 is a clinical study titled "Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and Impaired Renal Function". This is an open-label, single dose study designed to assess the pharmacokinetics and safety of ABT-493 and ABT-530 in subjects with either normal renal function or impaired renal function.
What is the current status of trial NCT02442258?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2015-03. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02442258?
The interventions under investigation include: ABT-493 (DRUG), ABT-530 (DRUG).
Who is sponsoring clinical trial NCT02442258?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.